rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANVS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Annovis Bio receives second positive safety review for AD trial
      Nov 17Investing.comANVS
      Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

      MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the Company’s pivotal Phase 3 trial in early AD, a

      Nov 17Yahoo FinanceANVS
      Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
      Nov 13Yahoo FinanceANVS
      Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman

      Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through th...

      Nov 9Business InsiderANVS
      Annovis Bio prices $21 million public offering at $1 per share
      Nov 5Investing.comANVS
      Annovis Announces Pricing of $21.0 Million Public Offering
      Nov 5Yahoo FinanceANVS
      Annovis Announces Launch of Proposed Public Offering

      MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnol...

      Nov 4Business InsiderANVS
      Annovis Bio announces proposed public offering
      Nov 4Investing.comANVS
      Annovis Bio Addresses NYSE Non-Compliance Listing Notice

      Tipranks Press Release.

      Oct 31The Globe and MailANVS
      Annovis Bio receives NYSE non-compliance notice
      Oct 30Investing.comANVS
      Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
      Oct 30Yahoo FinanceANVS
      Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

      Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updatesMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovi

      Oct 29Yahoo FinanceANVS
      Annovis to Attend the CTAD 2026 with Three Presentations
      Oct 22Yahoo FinanceANVS
      Annovis Bio partners with Weave Bio for NDA preparation
      Sep 23Investing.comANVS
      Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
      Sep 23Yahoo FinanceANVS
      Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

      Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

      Sep 8Yahoo FinanceANVS
      Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA

      Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements

      Sep 3Yahoo FinanceANVS
      Annovis to Host Corporate Update Webinar on September 2, 2026

      MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upc

      Aug 25Yahoo FinanceANVS

      This is the newest page. Registered accounts read further back.